RepliCel Life Sciences, Inc. operates as a regenerative medicine company. The company focuses on developing autologous cell therapies that address conditions linked to a deficit of healthy cells required for normal healing and function. Its products includes RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin, and pattern baldness. The company was founded on April 24, 1967 and is headquartered in Vancouver, Canada.
Company profile
Ticker
REPCF
Exchange
Website
CEO
Robert Lee Buckler
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
Former names
NEWCASTLE RESOURCES LTD., PAN AMERICAN GOLD CORP, TRI LATERAL VENTURE CORP
SEC CIK
REPCF stock data
Latest filings (excl ownership)
D
$86.94 k in equity, sold $86.94 k, 2 investors
25 Jan 23
6-K
RepliCel Announces Closing of Non-brokered Private Placement
17 Jan 23
6-K
RepliCel Announces Extension to Non-brokered Private Placement
17 Jan 23
D
$558.84 k in equity / options / securities to be acquired, sold $558.84 k, 2 investors
5 Jan 23
6-K
Current report (foreign)
8 Dec 22
6-K
Condensed Consolidated Interim Financial Statements
29 Nov 22
6-K
Current report (foreign)
25 Oct 22
UPLOAD
Letter from SEC
20 Sep 22
20-F/A
2021 FY
Annual report (foreign) (amended)
12 Sep 22
6-K
RepliCel Announces Non-brokered Private Placement
6 Sep 22
Latest ownership filings
SC 13D/A
Schutte Andrew
26 Jan 23
SC 13D/A
MACKAY JAMIE MYLES
5 Jan 23
SC 13D
MACKAY JAMIE MYLES
29 Sep 22
SC 13D/A
Schutte Andrew
2 Jun 22
SC 13D/A
MAINPOINTE PHARMACEUTICALS, LLC
21 Dec 21
SC 13D
MAINPOINTE PHARMACEUTICALS, LLC
4 Jun 21
SC 13D/A
Schutte Andrew
17 Sep 20
SC 13D
Replicel Life Sciences Inc.
12 Sep 18
Financial summary
| Quarter (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q3 2022
9.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 3.99 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Mainpointe Pharmaceuticals | 3.99 mm | $0.00 |